PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2042609
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2042609
Bioinformatics In IVD Testing Market size was valued at US$ 110,542.18 Million in 2025, expanding at a CAGR of 6.8% from 2026 to 2033.
Bioinformatics in IVD testing refers to the application of computational tools, algorithms, and biological data analysis to interpret complex diagnostic data generated from genomic, proteomic, and molecular tests. The Bioinformatics In IVD Testing market is experiencing strong growth driven by advancements in bioinformatics technologies, rising demand for personalized medicine, and increasing prevalence of chronic diseases. For instance, in 2025, analysis from the Health System Tracker. Org. that the U.S. has a substantially higher prevalence of key chronic conditions, including over twice the rate of obesity (about 42% of adults vs. ~17.8% in peer countries), around double the rate of diabetes (12.5% vs. 6.1%), and approximately 1.7 times higher asthma prevalence compared to peer nations. Americans have a higher chronic disease burden compared to peers in Canada, Europe, and Japan. Hence, rising disease burden is driving adoption of bioinformatics in IVD testing.
Bioinformatics In IVD Testing Market- Market Dynamics
Growing Use Of Personalized Medicine Is Driving Market Demand Growth
Personalized medicine is increasingly shaping the future of healthcare, driven by the use of big data and advanced digital technologies to enable more patient-specific prevention, diagnosis, and treatment approaches. It is enhancing early disease detection and supporting more precise, targeted therapies through the integration of molecular diagnostics and precision profiling, reducing dependence on traditional one-size-fits-all models.
The growing use of personalized medicine is driving the demand for bioinformatics in IVD testing, as it enables precise analysis of genetic and molecular data to support tailored diagnosis and treatment. For instance, in 2025, research under the European Commission highlights that personalized medicine is rapidly expanding across Europe as a key pillar of future healthcare systems, shifting clinical practice from generalized treatment models to precision-based approaches using genetic, molecular, and patient-specific data. The European research collaboration platform ICPerMed brings together over 30 countries and partners, enhancing research collaboration, data integration, and personalized medicine adoption across healthcare systems. The European Partnership for Personalized Medicine includes 49 organizations, supporting innovation, cross-border cooperation, and clinical implementation of precision medicine in Europe. Therefore, bioinformatics is driving faster adoption of precision-based healthcare and diagnostics.
The Global Bioinformatics In IVD Testing Market is segmented on the basis of Product Type, Type Of Test, Technology, Application, End User, and Region.
The blood-based tests segment within the Bioinformatics In IVD Testing market accounts for a significant share due to its critical role in enabling rapid, minimally invasive diagnostics and supporting the growing demand for precision medicine and early disease detection. For instance, according to NIH Gov, the growing emphasis on early disease detection is accelerating the adoption of advanced diagnostic and AI-based healthcare technologies. The review evaluated more than 106 observational studies involving nearly 22.7 million patients, with approximately 77.3% focused on disease diagnosis prediction and early-stage detection. These developments are accelerating adoption of blood-based bioinformatics diagnostics for early disease detection.
Based on technology, PCR occupies a key position in the Bioinformatics in IVD Testing market due to its high accuracy, quick turnaround time, and broad adoption in molecular diagnostics and infectious disease detection. For instance, according to research of the US government, the adoption of molecular diagnostics has accelerated significantly due to rapid advances in PCR. A survey of 5,301 hospitals showed that nearly 63% had implemented at least one rapid molecular assay for antimicrobial resistance detection, highlighting growing integration into healthcare workflows. Hence, increasing PCR adoption is accelerating growth in Bioinformatics In IVD Testing market.
Bioinformatics In IVD Testing Market- Geographical Insights
The regional outlook for Bioinformatics In IVD Testing market reveals a dynamic landscape with varying growth patterns across different regions. North America holds a prominent position in the market, supported by advanced healthcare infrastructure, widespread adoption of innovative technologies, and substantial investments in research and development activities. For instance, in 2025, as highlighted in the Commonwealth Fund's org, the nation's publicly funded healthcare system provides near-universal coverage, ensuring access for almost 100% of the population without direct point-of-care payments. The system operates through 13 provincial and territorial insurance plans under the Canada Health Act, ensuring national standards with regional healthcare administration. It is mainly tax-funded, with public spending accounting for over 70% of total health expenditure. Therefore, this robust system supports sustained growth in bioinformatics in IVD testing.
In contrast, the Asia Pacific region is expected to experience notable expansion in the Bioinformatics in IVD Testing market, driven by increasing healthcare spending, rising awareness of advanced diagnostics, and a growing burden of chronic diseases. For instance, in recent years, research highlighted on NIH.gov shows that China has been experiencing a steady rise in awareness of diagnostics, driven by improvements in healthcare infrastructure, expanding screening initiatives, and increased public health communication efforts. The study indicates that diagnostic awareness among healthcare providers and the general population has improved significantly, driven by the adoption of advanced diagnostic technologies and wider access to testing services. Hence, driving faster adoption of advanced bioinformatics-based diagnostic solutions.
Europe Bioinformatics In IVD Testing Market - Country Insights
Europe holds a position in the bioinformatics and IVD testing market, supported by a well-established healthcare system and ongoing medical research advancements. For instance, in 2025, data from the MedTech Europe Data Hub Org. show that Europe's medical technology sector continues to operate as one of the most innovation-driven ecosystems in global healthcare research, supported by R&D intensity and rapid product development cycles. The sector allocates about 8% of sales to R&D and operates with short 18-24 month product lifecycles, reflecting rapid, research-driven innovation and continuous clinical advancement. This innovation ecosystem strengthens Europe's leadership in bioinformatics-based diagnostic technologies.
The Bioinformatics In IVD Testing market is highly competitive, with established companies and emerging startups focusing on innovation, advanced tool development, and expanding solution portfolios. Key companies include Thermo Fisher Scientific, Illumina Inc., Qiagen N.V., Bio-Rad Laboratories Inc., and Agilent Technologies. In October 2025, Thermo Fisher Scientific announced the acquisition of Clario Holdings, a clinical data management and analytics company, for approximately USD 8.88 billion, aimed at strengthening its bioinformatics and clinical data capabilities to support advanced in vitro diagnostic (IVD) testing and precision medicine solutions through enhanced data integration and analytics platforms. This acquisition further strengthens the integration of bioinformatics and data-driven innovation in advanced diagnostic solutions.
In March 2026, Agilent Technologies Inc. announced a $950 million all-cash acquisition of Biocare Medical, a leading provider of immunohistochemistry and molecular pathology solutions, to strengthen its bioinformatics-enabled IVD testing portfolio and expand advanced clinical diagnostics capabilities across oncology and infectious disease applications.
In February 2026, Bio-Rad Laboratories Inc. expanded its molecular diagnostics and bioinformatics-driven IVD testing capabilities through the integration of Stilla Technologies and strategic partnerships in digital PCR and oncology assay development, strengthening its precision diagnostics and data-driven clinical testing ecosystem.